Abstract：Objective To assess the efficacy and safety of probiotics supplementation on anti-Helicobacter pylori levofloxacin-based second-line rescue therapy. Methods All relevant controlled trials (RCT) of probiotics reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy published before March 1, 2017 were collected by searching Pubmed, Embase, the Cochrane Library, CNKI, VIP, CBM and Wan Fang Data. All subjects were treated with anti-Helicobacter pylori levofloxacin-based rescue therapy. The experimental group was treated with probiotics at the same time, while the control group was treated without probiotics, and the process and the outcome of both groups were followed up. Two researchers used RevMan 5.2 to perform statistical analysis on the basis of literature screening, data extraction and quality evaluation (PEDro). Results Six RCTs included 430 patients with probiotics (experimental group) and 380 patients without probiotics (control group). The results of Meta-analysis: the PP-analysis results about the rate of Hp eradication of the groups with and without probiotics (OR=2.11, 95%CI=1.47~3.02, P＜0.0001); the ITT-analysis results about the rate of Hp eradication of the groups with and without probiotics (OR=2.01, 95%CI=1.43~2.81, P＜0.0001) and the comparative results of adverse reactions about the two groups (OR=0.63, 95%CI=0.40~0.99, P=0.05) were all statistically significant. Conclusion The probiotics reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy can effectively improve the rate of Hp eradication and reduce the side effects of the drugs.
